Myelitis clinical trials
The registry lists 13 studies for Myelitis across 7 countries. 3 are recruiting or about to start. 2 of them are mainly about Myelitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-09-24. Counting its 5 narrower conditions too, such as Poliomyelitis: 521 studies, 111 open.
Get an email when these change. Save the Myelitis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Johns Hopkins University (3) · National Institutes of Health Clinical Center (CC) (2) · Hospices Civils de Lyon (2) · Centre Hospitalier Universitaire de la Guadeloupe (1) · American CryoStem Corporation (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Mayo Clinic (1) · Oslo University Hospital (1)
What is being tested here
Drugs under test in Myelitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Azathioprine | 1 | 1 | 1 |
| 4-Aminopyridine | 0 | 0 | 1 |
| Methotrexate | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Dec 2026Azathioprine in MOGAD · Phase 3 · Hospices Civils de Lyon
Who these studies take
Of the 3 Myelitis studies recruiting now, 3 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (33%) | 1 (33%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 3 (100%) | 3 (100%) |
| 85 | 3 (100%) | 3 (100%) |
Across all 13 studies, recruiting or not: 38% stop at 75 or younger and 31% at 65; 31% take children; 0% are for women only and 0% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 13 of 13. search them.
- Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)RecruitingNCT07100990Phase 31 country
- Acute Infectious Encephalitis and Myelitis in Guadeloupe by New Generation SequencingRecruitingNCT072510491 country
- Azathioprine in MOGADRecruitingNCT05349006Phase 31 country
- The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)CompletedNCT028507051 country
- CNS Growth Factors Release and Changes in the Inflammatory Environment in Response to Electrical Stimulation in Subjects With Inflammatory MyelopathiesTerminatedNCT01440452Not applicable1 country
- Neurologic Manifestations of the Arbovirus Infection in ColombiaCompletedNCT032065411 country
- Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple SclerosisTerminatedNCT02326935Phase 11 country
- European Paediatric AFM Associated With EV-D68 Follow-up Study.Status unknownNCT03499366Not applicable1 country
- Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)CompletedNCT02166346Phase 21 country
- Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.WithdrawnNCT00037115Phase 41 country
- Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus DiseaseCompletedNCT00069316Phase 21 country
- Natural History of West Nile Virus InfectionCompletedNCT000693031 country
- IVIG - West Nile Encephalitis: Safety and EfficacyCompletedNCT00068055Phase 1/22 countries